SCHEMBL792525

SCHEMBL792525

CC(=O)c1ccc2c(C)c3n(c2c1)CC(=O)NCC3

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GFER P55789 2/20 0.41
HTR2A P28223 1/20 0.36
HTR2C P28335 1/20 0.36
POLB P06746 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
PARP10 Q53GL7 1/20 0.34
PARP11 Q9NR21 1/20 0.34
RPS6KA2 Q15349 1/20 0.33
KIF11 P52732 1/20 0.33
ALOX5 P09917 1/20 0.33
MAPT P10636 3/20 0.31
ALDH1A1 P00352 2/20 0.31
HPGD P15428 1/20 0.31
PARP1 P09874 1/20 0.31
BRD4 O60885 1/20 0.31
KCNJ1 P48048 1/20 0.31
SLC2A1 P11166 1/20 0.31
KDR P35968 1/20 0.31
NPC1 O15118 1/20 0.31
RAB9A P51151 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14572851 0.78 HTR2A (0.37) GFERHTR2AHTR2CRPS6KA2KIF11
SCHEMBL792496 0.77 GAA (0.41) HTR2AHTR2CPOLBKIF11ALOX5
SCHEMBL792527 0.76 ALDH1A1 (0.41) HTR2AHTR2CPOLBMAPTALDH1A1
SCHEMBL792128 0.74 SIGMAR1 (0.32) POLBALDH1A1NPC1
SCHEMBL792516 0.72 HTR7 (0.34) POLBALOX5MAPTALDH1A1HPGD
SCHEMBL792539 0.69 DRD3 (0.41) HTR2AHTR2CMAPTALDH1A1
SCHEMBL792524 0.67 FABP4 (0.45) HTR2AHTR2CPOLBALDH1A1HPGD
SCHEMBL792066 0.63 MTNR1A (0.47) MAPTNPC1RAB9APKM
SCHEMBL792576 0.61 MAPT (0.48) MAPTALDH1A1HPGDRAB9APKM
SCHEMBL13387223 0.61 MAPT (0.53) POLBTDP1KIF11MAPTALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR JAPAN TOBACCO INC. (JP) 2012-03-22 US disclosed
US-7977331-B1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2011-07-12 US disclosed
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor JAPAN TOBACCO INC. (JP) 2007-03-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070049593-A1 Tetracyclic fused heterocyclic compound and use thereof as HCV polymerase inhibitor POLI, TERT, ZC3HAV1 GFER 2960/4885HTR2A 4863/4885HTR2C 4660/4885
US-20120070409-A1 TETRACYCLIC FUSED HETEROCYCLIC COMPOUND AND USE THEREOF AS HCV POLYMERASE INHIBITOR POLI, TERT, ZC3HAV1 GFER 2960/4885HTR2A 4863/4885HTR2C 4660/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.